Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

@inproceedings{Jeannot2016SynergisticAO,
  title={Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma},
  author={Victor Jeannot and Benoit Busser and Laetitia Vanwonterghem and Sophie Michallet and Sana Ferroudj and Murat Cokol and Jean-Luc Coll and Mehmet Fatih Ozturk and Amandine Hurbin},
  booktitle={OncoTargets and therapy},
  year={2016}
}
Development of drug resistance limits the efficacy of targeted therapies. Alternative approaches using different combinations of therapeutic agents to inhibit several pathways could be a more effective strategy for treating cancer. The effects of the approved epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (gefitinib) or a multi-targeted kinase inhibitor (sorafenib) in combination with a histone deacetylase inhibitor (vorinostat) on cell proliferation, cell cycle distribution… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Citations
50 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 50 references

( NSCLC ) patients with epidermal growth factor receptor ( EGFR ) mutations after erlotinib progression

  • SE Witta, RM Jotte, K Konduri
  • 2014

Similar Papers

Loading similar papers…